Last reviewed · How we verify
Profilaxis recommended
This drug targets the SARS-CoV-2 spike protein to prevent infection.
This drug targets the SARS-CoV-2 spike protein to prevent infection. Used for Prevention of COVID-19.
At a glance
| Generic name | Profilaxis recommended |
|---|---|
| Sponsor | Maimónides Biomedical Research Institute of Córdoba |
| Drug class | vaccine |
| Target | SARS-CoV-2 spike protein |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
It works by binding to the spike protein, thereby preventing the virus from entering host cells. This mechanism of action is similar to other COVID-19 vaccines, but the specific formulation and delivery method may differ.
Approved indications
- Prevention of COVID-19
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. (PHASE3)
- Development of a Predictive Model for Sexually Transmitted Infections in Individuals Using Pre-Exposure Prophylaxis for HIV in Spain
- Randomized Clinical Trial, Open, Multicenter Parallel, no Suspension Inferiority Prophylactic Treatment With Valganciclovir in Kidney Transplant CMV-seropositive Cellular Immunity to Develop CD8 + CMV-specific Treatment After Induction Thymoglobulin. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Profilaxis recommended CI brief — competitive landscape report
- Profilaxis recommended updates RSS · CI watch RSS
- Maimónides Biomedical Research Institute of Córdoba portfolio CI